You are here
- Home
About SEROQUEL XR
What is SEROQUEL XR? SEROQUEL XR is an atypical antipsychotic indicated for the treatment of schizophrenia, bipolar disorder (bipolar mania, bipolar depression and the prevention of recurrence of bipolar disorder). SEROQUEL XR is a once-daily tablet of the extended release formulation of quetiapine fumarate. SEROQUEL XR dosed once daily is considered to be therapeutically equivalent to the immediate release formulation of SEROQUEL dosed twice daily
Bipolar disorder and schizophrenia are serious psychiatric disorders that require effective treatment and the role of SEROQUEL XR for the treatment of patients with these conditions is highlighted. You can find more information about Seroquel indications and efficacy on the Indications and Efficacy page.
SEROQUEL XR: schizophrenia
- SEROQUEL XR is an effective once-daily treatment for schizophrenia (acute and relapse prevention)[1],[2]
- SEROQUEL XR restores control of acute symptoms in patients with schizophrenia[1]
- SEROQUEL XR is effective at preventing relapse in stable schizophrenic patients who have been maintained on Seroquel XR2
SEROQUEL XR: bipolar disorder
- SEROQUEL XR is effective across all phases of bipolar disorder[3],[4]
SEROQUEL XR: bipolar mania
- SEROQUEL XR is a once-daily treatment for the moderate to severe manic episodes in bipolar disorder[3]
SEROQUEL XR: bipolar depression
- SEROQUEL XR is an effective once-daily treatment across a broad range of symptoms of bipolar depression[4]
SEROQUEL XR: prevention of recurrence in patients with bipolar disorder
- SEROQUEL XR is effective for the prevention of recurrence in patients with bipolar disorder, in patients whose manic or depressive episode has responded to SEROQUEL XR or SEROQUEL treatment[5],[6]
- SEROQUEL XR is an effective maintenance treatment for patients with bipolar I disorder as an adjunct to lithium or divalproex[7],[8]
References
- Kahn et al. J Clin Psychiatry 2007; 68: 832-842.
- Peuskens et al. Psychiatry (Edgemont) 2007; 4: 34-50.
- Cutler et al. Int J Neuropsychopharmacol 2008; 11(S1): 184-185.
- Suppes et al. J Affect Disord. 2010; 121: 106-15.
- Young et al. J Clin Psychiatry 2010 online publication.
- McElroy et al. J Clin Psychiatry 2010 online publication.
- Vieta et al. J Affect Disord. 2008; 109(3):251-63.
- Suppes et al. Am J Psychiatry. 2009; 166(4):476-88.